The haptoglobin blood test measures the level of haptoglobin in your blood.
Haptoglobin is a protein produced by the liver. It attaches to a certain type of hemoglobin in the blood. Hemoglobin is a blood cell protein that carries oxygen.
A blood sample is needed.
Certain medicines may affect the results of this test. Your health care provider will tell you if you need to stop taking any medicines. Do not stop any medicine before talking to your provider.
Drugs that can raise haptoglobin levels include:
Drugs that can lower haptoglobin levels include:
When the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or a slight bruise. This soon goes away.
This test is done to see how fast your red blood cells are destroyed. It may be done if your provider suspects you have a type of anemia that your immune system is causing.
The normal range is 41 to 165 milligrams per deciliter (mg/dL) or 410 to 1,650 milligrams per liter (mg/L).
Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or test different samples. Talk to your provider about the meaning of your specific test results.
When red blood cells are actively being destroyed, haptoglobin disappears faster than it is created. As a result, the levels of haptoglobin in the blood drop.
Lower than normal levels may be due to:
Higher-than-normal levels may be due to:
There is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another and from one side of the body to the other. Taking blood from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight but may include:
Marcogliese AN, Yee DL. Resources for the hematologist: interpretive comments and selected reference values for neonatal, pediatric, and adult populations. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 162.
Michel M. Autoimmune and intravascular hemolytic anemias. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 151.BACK TO TOP
Review Date: 2/6/2020
Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.